09/11/23 7:00 AMNasdaq : IVVD clinical trialcovid-19Invivyd Announces Dosing of First Participant in CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of Symptomatic COVID-19 Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced thatRHEA-AInegative
09/06/23 7:00 AMNasdaq : IVVD conferencesInvivyd to Participate in Upcoming Investor ConferencesInvivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced that it will present at the following investor conferences: H.C. WainwrightRHEA-AIvery negative
09/05/23 7:00 AMNasdaq : IVVD managementInvivyd Appoints William Duke as Chief Financial OfficerInvivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced the appointment of William Duke as Chief Financial Officer. Mr. Duke will leadRHEA-AIneutral
08/10/23 4:01 PMNasdaq : IVVD earningsInvivyd Reports Second Quarter 2023 Financial Results and Business Highlights Reported p ositive initial Phase 1 VYD222 clinical trial data , including favorable safety data and robust serum neutralizing titers from all three dose levels tested Plans to pursue rapid initiation of a 750-participant pivotal clinical trial of VYD222 (CANOPY) that will utilize Day 28 serumRHEA-AIneutral
08/03/23 4:01 PMNasdaq : IVVD conferencesearningsInvivyd to Host Conference Call Discussing Second Quarter 2023 Financial Results and Business HighlightsInvivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced that it will host a conference call on Thursday, August 10, 2023, at 4:30 p.m.RHEA-AIvery negative
07/27/23 4:01 PMNasdaq : IVVD managementInvivyd Announces Appointment of Sara Cotter to Board Of DirectorsInvivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced the appointment of Sara Cotter to its board of directors. Ms. Cotter bringsRHEA-AIneutral
07/17/23 7:00 AMNasdaq : IVVD clinical trialcovid-19Invivyd Announces Additional Positive Initial Data from Ongoing Phase 1 Clinical Trial of VYD222, a Monoclonal Antibody Candidate in Development for the Prevention of Symptomatic COVID-19 in Immunocompromised PeopleContinued favorable safety and tolerability profile for all dose levels tested Serum samples from all dose levels tested showed robust neutralization activity against Omicron XBB.1.5, one of the dominant SARS-CoV-2 variants circulating globally Ongoing analysis of serum neutralizing activity andRHEA-AIneutral
06/26/23 7:00 AMNasdaq : IVVD covid-19Invivyd Announces General Alignment with FDA on Pathway to Potential EUA for VYD222 and Anticipated Follow-On Monoclonal Antibody Candidates Designed to Prevent COVID-19Unique, rapid development pathway for monoclonal antibodies (mAbs) using immunobridging via serum neutralizing titers could be enabled by previously generated clinical trial data from prototype antibody VYD222 and potential future Invivyd mAbs are planned to leverage this EUA pathway usingRHEA-AIneutral
06/22/23 7:00 AMNasdaq : IVVD clinical trialcovid-19Invivyd Announces Positive Initial Data from Ongoing Phase 1 Clinical Trial of VYD222, a Monoclonal Antibody Candidate in Development for the Prevention of Symptomatic COVID-19 in Immunocompromised PeopleVYD222 has been generally well-tolerated at all dose levels, with no serious adverse events reported to date As predicted by pre-clinical in vitro testing, early serum samples from the first, lowest dose cohort showed strong neutralization activity against Omicron XBB.1.5, one of the dominantRHEA-AIneutral
06/01/23 7:00 AMNasdaq : IVVD conferencesInvivyd to Participate at the Jefferies Healthcare ConferenceInvivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced that David Hering, chief executive officer of Invivyd, is scheduled to presentRHEA-AIvery negative